

Myocardial Fibrosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

<https://marketpublishers.com/r/M4B1E3900347EN.html>

Date: July 2020

Pages: 71

Price: US\$ 1,599.00 (Single User License)

ID: M4B1E3900347EN

Abstracts

2020 Myocardial Fibrosis PIPELINE HIGHLIGHTS

Myocardial Fibrosis is one of the widely researched conditions during 2020 with 14 companies actively focusing on realizing pipeline's potential. Development of Myocardial Fibrosis medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Myocardial Fibrosis market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Myocardial Fibrosis.

Good progress is anticipated during 2020 and 2021 with Myocardial Fibrosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Myocardial Fibrosis pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Myocardial Fibrosis DRUG DEVELOPMENT PIPELINE OVERVIEW

The "Myocardial Fibrosis pipeline Research Monitor, 2020" report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Myocardial Fibrosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Myocardial Fibrosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Myocardial Fibrosis pipeline. Information on R&D pipeline

updates, results of key clinical trials are also included in the report.

Myocardial Fibrosis DRUG PROFILES

Myocardial Fibrosis development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.

Phase of development

Mechanism of Action

Route of Administration

Companies involved including originator, licensing companies, developer, investors, and others

New molecular entity details

Orphan drug designation and other special status provided by regulators

Myocardial Fibrosis COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Myocardial Fibrosis drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Myocardial Fibrosis. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 14 Myocardial Fibrosis companies including company overview, key snapshot, contact information, and their strategies on accelerating Myocardial Fibrosis pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Ember Therapeutics Inc, Evotec SE,

Galectin Therapeutics Inc, Haya Therapeutics , Invivosciences Inc, Lead Discovery Center GmbH, Liminal BioSciences Inc, MandalMed Inc, Merck & Co Inc, NovoMedix LLC , Palatin Technologies Inc , Pharmaxis Ltd , TRACON Pharmaceuticals Inc, Vectus Biosystems Ltd

REASONS TO BUY

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.

This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data

Buyers can identify most promising drug candidates for treatment of Myocardial Fibrosis

It allows users to strengthen their pipeline through acquisitions, licensing and collaborations

Users can estimate possible delays in the delivery of pipeline or launch of new products

Stay ahead of competition through understanding their pipeline progression, strategies and outlook

The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.

Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO MYOCARDIAL FIBROSIS

- 1.1 Myocardial Fibrosis- Disease overview
- 1.2 Myocardial Fibrosis- Market Size
- 1.3 Myocardial Fibrosis- Companies Involved

2. MYOCARDIAL FIBROSIS PIPELINE SNAPSHOT- 2020

- 2.1 Myocardial Fibrosis Pipeline by Phase
- 2.2 Myocardial Fibrosis Pipeline by Mechanism of Action
- 2.3 Myocardial Fibrosis Pipeline by Route of Administration
- 2.4 Myocardial Fibrosis Pipeline- New Molecular Entities
- 2.5 Myocardial Fibrosis Pipeline- Orphan Drug Designation/ Special Designation

3. MYOCARDIAL FIBROSIS DRUG PROFILES

- 3.1 Current Status
- 3.2 Myocardial Fibrosis Drug Snapshot
- 3.3 Myocardial Fibrosis Therapeutic Candidates- Originator/Licensors
- 3.4 Route of Administration
- 3.5 Mechanism of Action
- 3.6 NME
- 4.1 Ember Therapeutics Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.2 Evotec SE Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.3 Galectin Therapeutics Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.4 Haya Therapeutics Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.5 Invivosciences Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.6 Lead Discovery Center GmbH Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.7 Liminal BioSciences Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.8 MandalMed Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.9 Merck & Co Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.10 NovoMedix LLC Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.11 Palatin Technologies Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.12 Pharmaxis Ltd Myocardial Fibrosis Pipeline Insights and Clinical Trials
- 4.13 TRACON Pharmaceuticals Inc Myocardial Fibrosis Pipeline Insights and Clinical Trials

4.14 Vectus Biosystems Ltd Myocardial Fibrosis Pipeline Insights and Clinical Trials

5. MYOCARDIAL FIBROSIS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology

6.2 Contact Information

I would like to order

Product name: Myocardial Fibrosis pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

Product link: <https://marketpublishers.com/r/M4B1E3900347EN.html>

Price: US\$ 1,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M4B1E3900347EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

